Cloned peripheral nerve, tetrodotoxin-resistant sodium channel alpha-subunit

ABSTRACT

The present invention relates to a voltage-gated sodium channel present in peripheral nerve tissue that is tetrodotoxin-resistant. One aspect of the present invention is purified and isolated DNA encoding this sodium channel. Another aspect of the present invention is the recombinant protein expressed by this DNA, expression vectors comprising the DNA sequence, and host cells transformed with these expression vectors. Another aspect of this invention is the use of this voltage-gated, tetrodotoxin-resistant sodium channel as a therapeutic target for compounds to treat disorders of the peripheral nervous system.

CROSS REFERENCES TO RELATED APPLICATION

This application is a continuation-in-part of U.S. Ser. No. 08/511,828,filed Oct. 11, 1995, pending, the disclosure of which is incorporated byreference herein.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The basic unit of information transmitted from one part of the nervoussystem to another is a single action potential or nerve impulse. The“transmission line” for these impulses is the axon, or nerve fiber. Theelectrical excitability of the nerve membrane has been shown to dependon the membrane's voltage-sensitive ionic permeability system thatallows it to use energy stored in ionic concentration gradients.Electrical activity of the nerve is triggered by a depolarization of themembrane, which opens channels through the membrane that are highlyselective for sodium ions, which are then driven inward by theelectrochemical gradient. Of the many ionic channels, the voltage-gatedor voltage-sensitive sodium channel is one of the most studied. It is atransmembrane protein that is essential for the generation of actionpotentials in excitable cells.

The cDNAs for several Na⁺ channels have been cloned and sequenced. Thesestudies have shown that the amino acid sequence of the Na⁺ channel hasbeen conserved over a long evolutionary period. These studies have alsorevealed that the channel is a single polypeptide containing fourinternal repeats, or homologous domains (domains I-IV), having similaramino acid sequences. Each domain folds into six predicted transmembraneα-helices or segments: five are hydrophobic segments and one is highlycharged with many lysine and arginine residues. This highly chargedsegment is the fourth transmembrane segment in each domain (the S4segment) and is likely to be involved in voltage-gating. The positivelycharged side chains on the S4 segment are likely to be paired with thenegatively charged side chains on the other five segments such thatmembrane depolarization could shift the position of one helix relativeto the other, thereby opening the channel. Accessory subunits may modifythe function of the channel.

There is a significant therapeutic utility in recombinant materialsderived from the DNA of the numerous sodium channels that have beendiscovered. For example, the recombinant protein can be used to screenfor potential therapeutics that have the ability to inhibit the sodiumchannel of interest. In particular, it would be useful to inhibitselectively the function of sodium channels in nerve tissues responsiblefor transmitting pain and pressure signals without simultaneouslyaffecting the function of sodium channels in other tissues such asmuscle, heart and brain. Such selectivity would allow for the treatmentof pain without causing side effects due to cardiac, central nervoussystem or neuromuscular complications. Therefore, it would be useful tohave DNA sequences coding for sodium channels that are selectivelyexpressed in peripheral sensory nerve tissue. Though cDNAs from ratskeletal muscle, heart and brain are known, identification and isolationof cDNA from peripheral sensory nerve tissue, such as dorsal rootganglia, has been hampered by the difficulty of working with suchtissue.

This invention relates to a cloned α-subunit of a voltage-gatedtetrodotoxin-resistant sodium channel protein expressed in peripheralnerve tissue. This invention further relates to its production byrecombinant technology and nucleic acid sequences encoding for thisprotein.

2. Summary of Related Art

An excellent review of sodium channels is presented in Catterall, TINS16(12):500-506 (1993).

Purified Na⁺ channels have proven useful as therapeutic and diagnostictools, Cherksey, U.S. Pat. No. 5,132,296.

The cDNAs for several Na⁺ channels have been cloned and sequenced. Numa,et al., Annals of the New York Academy of Sciences 479:338-355 (1986),describes cDNA from the electric organ of eel and two different onesfrom rat brain. Rogart, U.S. Pat. No. 5,380,836 describes cDNA from ratcardiac tissue. See also Rogart, Cribbs et al. Proc. Natl. Acad. Sci.,86:8170-8174 (1989). A peripheral nerve sodium channel, referred to asPN1, has been detected based on sodium current studies and hybridizationto a highly conserved sodium channel probe by D'Arcangelo, et al., J.Cell Biol. 122:915-921 (1993). However, neither the DNA nor the proteinwere isolated and its complete nucleic acid and amino acid sequenceremained unidentified. A partial amino acid sequence was presented atthe 23rd Annual Meeting of the Society for Neuroscience, Nov. 7-12,1993, Washington D.C., see Abstracts: Volume 19, Part 1: Abstract 121.7:“Nerve Growth Factor Treatment of PC12 Cells Induces the Expression of aNovel Sodium Channel Gene, Peripheral Nerve Type 1 (PN1)”, by B. L.Moss, J. Toledo-Aral and G. Mandel.

Tetrodotoxin (“TTX”), a highly potent toxin from the puffer or Fugufish, blocks the conduction of nerve impulses along axons and inexcitable membranes of nerve fibers, which leads to respiratoryparalysis. TTX also binds very tightly to the Na⁺ channel and blocks theflow of sodium ions. The positively charged group of the toxin interactswith a negatively charged carboxylate at the mouth of the channel on theextracellular side of the membrane, thus obstructing the conductancepathway.

Studies using TTX as a probe have shed much light on the mechanism andstructure of Na⁺ channels. There are three Na⁺ channel subtypes, definedby the affinity for TTX, which can be measured by the IC₅₀ values:TTX-sensitive Na⁺ channels (IC₅₀≈1 nM), TTX-insensitive Na⁺ channels(IC₅₀≈1-5 μM), and TTX-resistant Na⁺ channels (IC₅₀≧100 μM).

TTX-insensitive action potentials were first studied in rat skeletalmuscle. Redfern, et al., Acta Physiol. Scand. 82:70-78 (1971).Subsequently, these action potentials were described in other mammaliantissues, including newborn mammalian skeletal muscle, mammalian cardiacmuscle, mouse dorsal root ganglion cells in vitro and in culture,cultured mammalian skeletal muscle and L6 cells. Rogart, Ann. Rev.Physiol. 43:711-725 (1980).

Dorsal root ganglia neurons possess both TTX-sensitive (IC₅₀≅0.3 nM) andTTX-resistant (IC₅₀≅100 μM) sodium channel currents, as described inRoy, et al., J. Neurosci. 12:2104-2111 (1992).

TTX-resistant sodium currents have also been measured in rat nodose andpetrosal ganglia, Ikeda, et al., J. Neurophysiol. 55:527-539 (1986) andStea, et al., Neurosci. 47:727-736 (1992).

SUMMARY OF THE INVENTION

One aspect of the present invention is a purified and isolated DNAsequence encoding for a mammalian peripheral nerve sodium channelprotein, in particular, the α-subunit of this protein. A preferredembodiment of the invention is a purified and isolated DNA sequenceencoding a mammalian peripheral nerve TTX-resistant sodium channel.

Further aspects of the invention include expression vectors comprisingthe DNA of the invention, host cells transformed or transfected by thesevectors, specifically mammalian cells, and a cDNA library of these hostcells.

Another aspect of the present invention is a recombinant polynucleotidecomprising a nucleic acid sequence derived from the DNA sequence of thisinvention.

Still another aspect of the invention is the rat and human peripheralnerve TTX-resistant sodium channel protein encoded by the DNA of thisinvention.

Also forming part of this invention is an assay for inhibitors of theperipheral nerve TTX-resistant sodium channel protein comprisingcontacting a compound suspected of being an inhibitor with expressedsodium channel and measuring the activity of the sodium channel.

Further provided is a method of inhibiting the activity of theperipheral nerve TTX-resistant sodium channel comprising administeringan effective amount of a compound having an IC₅₀ of 10 μM or less.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A-E depicts the 6344 nucleotide cDNA sequence encoding the ratperipheral nerve sodium channel type 3 (“PN3”) comprising a 5868-baseopen reading frame (SEQ ID NO:1). Nucleotide residue 23 represents thestart site of translation and residue 5893 represents the end of thestop codon.

FIG. 2 depicts the deduced amino acid sequence of PN3 (SEQ ID NO:2).Also shown are the homologous domains (I-IV); the putative transmembranesegments (51—S6); potential cAMP-dependent phosphorylation sites (o);potential N-linked glycosylation sites (●); the TTX resistance site (♦);the termination codon (*); and the site where several partial PN3 clonescontained an additional Gln between Pro⁵⁸⁴ and Ala⁵⁸⁵ (

).

FIG. 3 depicts a frequency histogram of somal area of DRG cells analyzedby in situ hybridization with a PN3 probe.

FIG. 4(a)-(c) shows the properties of currents induced in Xenopusoocytes by injection of PN3 cRNA.

FIG. 5 depicts the 5874 nucleotide open reading frame DNA sequence,assembled from cDNA and PCR fragments, encoding the human peripheralnerve sodium channel type 3 (“hPN3”)(SEQ ID NO:9).

FIG. 6 depicts the deduced amino acid sequence of hPN3 (SEQ ID NO:10).

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to sodium channel proteins present inperipheral nerve tissue. Specific embodiments include such sodiumchannels that are TTX-resistant and are expressed exclusively in sensoryneurons. Degenerate oligonucleotide-primed RT-PCR analysis was performedon RNA from the rat central and peripheral nervous systems, inparticular from rat dorsal root ganglia (“DRG”). The α-subunit of avoltage-gated, TTX-resistant sodium channel from rat DRG has been clonedand functionally expressed in Xenopus oocytes.

In particular, the present invention relates to a purified and isolatedDNA sequence encoding for a rat peripheral nerve TTX-resistant sodiumchannel. The term “purified and isolated DNA” refers to DNA that isessentially free, i.e. contains less than about 30%, preferably lessthan about 10%, and even more preferably less than about 1% of the DNAwith which the DNA of interest is naturally associated. Techniques forassessing purity are well known to the art and include, for example,restriction mapping, agarose gel electrophoresis, and CsCl gradientcentrifugation. The term “DNA” is meant to include cDNA made by reversetranscription of mRNA or by chemical synthesis.

Specifically, the invention relates to DNA having the nucleotidesequence set forth in FIG. 1 (SEQ ID NO:1). More generally, the DNAsequence comprises a cDNA sequence that encodes the α-subunit of avoltage-gated TTX-resistant sodium channel, specifically the amino acidsequence set forth in FIG. 2 (SEQ ID NO: 2). DNA sequences encoding thesame or allelic variant or analog sodium channel protein polypeptides ofthe peripheral nervous system, through use of, at least in part, ofdegenerate codons are also contemplated by this invention. The DNAsequence of FIG. 1 corresponds to the cDNA from rat. However, it isbelieved that a voltage-gated TTX-resistant sodium channel is alsoexpressed in peripheral nerve tissue of other mammalian species such ashumans, and that the corresponding gene is highly homologous to the ratsequence. Therefore, the invention includes cDNA encoding a mammalianvoltage-gated, TTX-resistant sodium channel.

The present invention also relates to a purified and isolated DNAsequence encoding a human peripheral nerve TTX-resistant sodium channel.Specifically, the invention includes DNA having the nucleotide sequenceset forth in FIG. 5 (SEQ ID NO: 9), which sets forth the human PN3,assembled from cDNA and PCR fragments. More generally, the DNA sequencecomprises a sequence that encodes the α-subunit of a voltage-gatedTTX-resistant sodium channel, specifically the amino acid sequence setforth in FIG. 6 (SEQ ID NO:10).

The 1956-amino acid protein encoded by the cDNA of the invention isdesignated herein as peripheral nerve sodium channel type 3 (“PN3”). TheDNA sequence in FIG. 1 is the cDNA sequence that encodes PN3, and thededuced amino acid sequence is set forth in FIG. 2 (SEQ ID NO:2).Reverse transcription-polymerase chain reaction (“RT-PCR”) analysis ofRNA from selected rat tissues indicates that PN3 expression is limitedto sensory neurons of the peripheral nervous system. A preferred aspectof this invention are cDNA sequences which encode for mammalianTTX-resistant sodium channel proteins that are expressed exclusively inthe sensory neurons of the peripheral nervous-system. The term“exclusively expressed” means that the sodium channel mRNA is found indorsal root ganglia, nodose ganglia and sciatic nerve but not in brain,spinal cord, heart, skeletal muscle or superior cervical ganglia whenassayed by the methods described herein, such as RT-PCR. cDNA sequenceswhich encode for TTX-resistant sodium channel proteins that arepredominantly expressed in the sensory neurons of the peripheral nervoussystem are also contemplated by this invention. The term “predominantlyexpressed” means that greater than 95% of the expression of the sodiumchannel occurs in the particular tissue cited. In situ hybridization torat DRG demonstrated that PN3 mRNA is present primarily in small DRGneurons. In addition, PN3 was shown to be a voltage-gated sodium channelwith a depolarized activation potential, slow inactivation kinetics, andresistant to a high concentration of TTX.

The term “cDNA” or complementary DNA refers to single-stranded ordouble-stranded DNA sequences obtained by reverse transcription of mRNAisolated from a donor cell. For example, treatment of mRNA with areverse transcriptase such as AMV reverse transcriptase or M-MuLVreverse transcriptase in the presence of an oligonucleotide primer willfurnish an RNA-DNA duplex which can be treated with RNase H, DNApolymerase, and DNA ligase to generate double-stranded cDNA. If desired,the double-stranded cDNA can be denatured by conventional techniquessuch as heating to generate single-stranded cDNA. The term “cDNA”includes cDNA that is a complementary copy of the naturally occurringmRNA as well as complementary copies of variants of the naturallyoccurring mRNA, that have the same biological activity. Variants wouldinclude, for example, insertions, deletions, sequences with degeneratecodons and alleles. An example of an insertion is a single additionalGln codon between the Pro⁵⁸⁴ and Ala⁵⁸⁵ codons of the full-length cDNAsequence of PN3, found in several clones.

The term “cRNA” refers to RNA that is a copy of the mRNA transcribed bya cell. CRNA corresponding to mRNA transcribed from a DNA sequenceencoding the α-subunit of a mammalian peripheral nerve TTX resistantsodium channel protein is contemplated by this invention.

As mentioned above, it is believed that homologs of the ratTTX-resistant sodium channel described herein are also expressed inother mammalian peripheral nerve tissue, in particular, human tissue.The rat sodium channel cDNA of the present invention can be used as aprobe to discover whether a voltage-gated TTX-resistant sodium channelexists in human peripheral nerve tissue and, if it does, to aid inisolating the cDNA for the human protein.

The human homologue of the rat TTX-resistant PN3 can be cloned using ahuman DRG cDNA library. Human DRG are obtained at autopsy. The frozentissue is homogenized and the RNA extracted with guanidineisothiocyanate (Chirgwin, et al. Biochemistry 18:5294-5299, 1979). TheRNA is size-fractionated on a sucrose gradient to enrich for large mRNAsbecause the sodium channel α-subunits are encoded by large (7-11 kb)transcripts. Double-stranded cDNA is prepared using the SuperscriptChoice cDNA kit (GIBCO BRL) with either oligo(dT) or random hexamerprimers. EcoRI adapters are ligated onto the double-stranded cDNA whichis then phosphorylated. The cDNA library is constructed by ligating thedouble-stranded cDNA into the bacteriophage-lambda ZAP II vector(Stratagene) followed by packaging into phage particles.

Phage are plated out on 150 mm plates on a lawn of XLI-Blue MRF1bacteria (Stratagene) and plaque replicas are made on Hybond N nylonmembranes (Amersham). Filters are hybridized to a rat PN3 cDNA or CRNAprobe by standard procedures and detected by autoradiography orchemiluminescence. The signal produced by the rat PN3 probe hybridizingto positive human clones at high stringency should be stronger thanobtained with rat brain sodium channel probes hybridizing to theseclones. Positive-plaques are further purified by limiting dilution andrescreened by hybridization or PCR. Restriction mapping and polymerasechain reaction will identify overlapping clones that can be assembled bystandard techniques into the full-length human homologue of rat PN3. Thehuman clone can be expressed by injecting CRNA transcribed in vitro fromthe full-length cDNA clone into Xenopus oocytes, or by transfecting amammalian cell line with a vector containing the cDNA linked to asuitable promoter.

The human homologue of the rat TTX-resistant PN3 was cloned using theprocedure outlined above. From human DRG, RNA was extracted and used toprepare cDNA and the cDNA library. The human PN3 was then obtained usinga PN3 probe, and expressed as described above. A comparison of the humanPN3 sequence (SEQ ID NO:10) to other known human and rat voltage-gatedsodium channels revealed that the greatest homology is with the rat PN3channel, where the corresponding human gene is 83% homologous to the ratsequence. The most closely related human channel is the heart I channel,having 64% identity for the amino acid sequence. A similar relationshipwas observed for rat PN3 in that the most closely related channel wasthe rat heart channel. A variant of rat PN3 was detected in which anextra Gln residue was present in the interdomain I/II loop, however, nosuch variant was found in the human DRG. The PN3 and SNS rat DRG sodiumchannels are very closely related and differ by only seven residues. Sixof these seven residues are identical in the human PN3 and rat PN3, sothat the human PN3 is more similar to the rat PN3 than to the SNSchannel.

Analysis of the open reading frame revealed that the human PN3 sequencehas all the hallmark structural features of sodium channels that arepredicted from the amino acid sequence: 24 transmembrane segments,charged residues in the S4 transmembrane segments, and the IFM sequencewithin the highly conserved interdomain II-IV region which constitutesthe fast inactivation gate. In addition the human PN3 channel had theidentical sequence as rat PN3 for the TTX-sensitivity site within thedomain I S5-S6 loop, where there is a Ser in position 357 in human PN3and position 356 in rat PN3, rather than a Cys residue which is presentin all other, that is non-PN3 type, TTX-insensitive/resistant channels.The human and rat channels also shared N-glycosylation consensus sitesand cAMP-dependent kinase sites which included several unusual sites indomain II and interdomain II-III.

The present invention also includes expression vectors comprising theDNA or the cDNA described above, host cells transformed with theseexpression vectors capable of producing the sodium channel of theinvention, and cDNA libraries comprising such host cells.

The term “expression vector” refers to any genetic element, e.g., aplasmid, a chromosome, a virus, behaving either as an autonomous unit ofpolynucleotide expression within a cell or being rendered capable ofreplication by insertion into a host cell chromosome, having attached toit another polynucleotide segment, so as to bring about the replicationand/or expression of the attached segment. Suitable vectors include, butare not limited to, plasmids, bacteriophages and cosmids. Vectors willcontain polynucleotide sequences which are necessary to effect ligationor insertion of the vector into a desired host cell and to effect theexpression of the attached segment. Such sequences differ depending onthe host organism, and will include promoter sequences to effecttranscription, enhancer sequences to increase transcription, ribosomalbinding site sequences and transcription and translation terminationsequences.

The term “host cell” generally refers to prokaryotic or eukaryoticorganisms and includes any transformable or transfectable organism whichis capable of expressing a protein and can be, or has been, used as arecipient for expression vectors or other transferred DNA. Host cellscan also be made to express protein by direct injection with exogenousCRNA translatable into the protein of interest. A preferred host cell isthe Xenopus oocyte.

The term “transformed” refers to any known method for the insertion offoreign DNA or RNA sequences into a host prokaryotic cell. The term“transfected” refers to any known method for the insertion of foreignDNA or RNA sequences into a host eukaryotic cell. Such transformed ortransfected cells include stably transformed or transfected cells inwhich the inserted DNA is rendered capable of replication in the hostcell. They also include transiently expressing cells which express theinserted DNA or RNA for limited periods of time. The transformation ortransfection procedure depends on the host cell being transformed. Itcan include packaging the polynucleotide in a virus as well as directuptake of the polynucleotide, such as, for example, lipofection ormicroinjection. Transformation and transfection can result inincorporation of the inserted DNA into the genome of the host cell orthe maintenance of the inserted DNA within the host cell in plasmidform. Methods of transformation are well known in the art and include,but are not limited to, viral infection, electroporation, lipofectionand calcium phosphate mediated direct uptake.

It is to be understood that this invention is intended to include otherforms of expression vectors, host cells and transformation techniqueswhich serve equivalent functions and which become known to the arthereto.

The term “cDNA library” refers to a collection of clones, usually in abacteriophage, or less commonly in bacterial plasmids, containing cDNAcopies of mRNA sequences derived from a donor cell or tissue.

In addition, the present invention contemplates recombinantpolynucleotides, of about 15 to 20 kb, preferably 10 to 15 kbnucleotides in length, comprising a nucleic acid sequence segment of theDNA of SEQ ID NOs: 1 and 9. The invention also includes a recombinantpolynucleotide comprising a nucleic acid subsequence derived from theDNA of SEQ ID NOs: 1 and 9. The term “subsequence” refers to a nucleicacid sequence having substantially the same DNA as the sequence of theinvention, having certain nucleotide additions or deletions.

The term “polynucleotide” as used herein refers to a polymeric form ofnucleotides of any length, either ribonucleotides ordeoxyribonucleotides. This term refers only to the primary structure ofthe molecule. Thus, this term includes double- and single-stranded DNA,as well as double- and single-stranded RNA. It also includes modified,for example, by methylation and/or by capping, and unmodified forms ofthe polynucleotide. The term “derived from” a designated sequence,refers to a nucleic acid sequence that is comprised of a sequence ofapproximately at least 6-8 nucleotides, more preferably at least 10-12nucleotides, and, even more preferably, at least 15-20 nucleotides thatcorrespond to, i.e., are homologous or complementary to, a region of thedesignated sequence. The derived sequence is not necessarily physicallyderived from the nucleotide sequence shown, but may be derived in anymanner, including for example, chemical synthesis or DNA replication orreverse transcription, which are based on the information provided bythe sequences of bases in the region(s) from which the polynucleotide isderived. Further, the term “polynucleotide” is intended to include arecombinant polynucleotide, which is of genomic, cDNA, semisynthetic orsynthetic origin which, by virtue of its origin or manipulation is notassociated with all or a portion of the polynucleotide with which it isassociated in nature and/or is linked to a polynucleotide other thanthat to which it is linked in nature.

The polynucleotides of the invention can be bound to a reporter moleculeto form a polynucleotide probe useful for Northern and Southern blotanalysis and in situ hybridization.

The term “reporter molecule” refers to a chemical entity capable ofbeing detected by a suitable detection means, including, but not limitedto, spectrophotometric, chemiluminescent, immunochemical, orradiochemical means. The polynucleotides of this invention can beconjugated to a reporter molecule by techniques well known in the art.Typically the reporter molecule contains a functional group suitable forattachment to or incorporation into the polynucleotide. The functionalgroups suitable for attaching the reporter group are usually activatedesters or alkylating agents. Details of techniques for attachingreporter groups are well known in the art. See, for example, Matthews,J. A., Batki, A., Hynds, C., and Kricka, L. J., Anal. Biochem.,151:205-209 (1985) and Engelhardt et al., European Patent ApplicationNo. 0 302 175.

The invention not only includes the entire protein expressed by the cDNAsequence of FIG. 1, but also includes protein fragments. These fragmentscan be obtained by cleaving the full length protein or by using smallerDNA sequences or polynucleotides to express the desired fragment.Accordingly, the invention also includes polynucleotides that can beused to make polypeptides of about 10 to 1500, preferably 10 to 100,amino acids in length. The isolation and purification of suchrecombinant polypeptides can be accomplished by techniques that are wellknown in the art, for example preparative chromatographic separations oraffinity chromatography. In addition, polypeptides can also be made bysynthetic means such as are well known in the art.

The polypeptides of the invention are highly useful for the developmentof antibodies against PN3. Such antibodies can be used in affinitychromatography to purify recombinant sodium channel proteins orpolypeptides, or they can be used as a research tool. For example,antibodies bound to a reporter molecule can be used in histochemicalstaining techniques to identify other tissues and cell types where PN3is present, or they can be used to identify epitopic or functionalregions of the sodium channel protein of the invention.

The antibodies can be monoclonal or polyclonal and can be prepared bytechniques that are well known in the art. Polyclonal antibodies areprepared as follows: an immunogenic conjugate comprising PN3 or afragment thereof, optionally linked to a carrier protein, is used toimmunize a selected mammal such as a mouse, rabbit, goat, etc. Serumfrom the immunized mammal is collected and treated according to knownprocedures to separate the immunoglobulin fraction. Monoclonalantibodies are prepared by standard hybridoma cell technology based onthat reported by Kohler and Milstein in Nature 256:495-497 (1975):spleen cells are obtained from a host animal immunized with the PN3protein or a fragment thereof, optionally linked to a carrier. Hybridcells are formed by fusing these spleen cells with an appropriatemyeloma cell line and cultured. The antibodies produced by the hybridcells are screened for their ability to bind to expressed PN3 protein. Anumber of screening techniques well known in the art, such as, forexample, forward or reverse enzyme-linked immunosorbent assay screeningmethods may be employed. The hybrid cells producing such antibodies arethen subjected to recloning and high dilution conditions in order toselect a hybrid cell that secretes a homogeneous population ofantibodies specific to the PN3 protein. In addition, antibodies can beraised by cloning and expressing nucleotide sequences or mutagenizedversions thereof coding at least for the amino acid sequences requiredfor specific binding of natural antibodies, and these expressed proteinsused as the immunogen. Antibodies may include the completeimmunoglobulin or a fragment thereof. Antibodies may be linked to areporter group such as is described above with reference topolynucleotides.

As mentioned above, the invention pertains to the cloning and functionalexpression, in Xenopus oocytes, of a rat peripheral nerve TTX-resistantsodium channel. Specifically, the α-subunit of the sodium channel wascloned and expressed. Accordingly, the invention encompasses a ratperipheral nerve TTX-resistant sodium channel α-subunit encoded by thecDNA set forth in FIG. 1, and fragments thereof. Specifically, theinvention includes the sodium channel α-subunit having the amino acidsequence set forth in FIG. 2, and fragments thereof. Additionally, theinvention encompasses a human peripheral nerve TTX-resistant sodiumchannel α-subunit encoded by the cDNA set forth in FIG. 5, (SEQ ID NO:9) and fragments thereof. Specifically, the invention includes thesodium channel α-subunit having the amino acid sequence set forth inFIG. 6, (SEQ ID NO:10) and fragments thereof.

The sodium channel comprises an α- and a β-subunit. The β-subunit maymodulate the function of the channel. However, since the α-subunit isall that is required for the channel to be fully functional, theexpression of the cDNA in FIG. 1, will provide a fully functionalprotein. The gene encoding the β-subunit in peripheral nerve tissue wasfound to be identical to that found in rat heart, brain and skeletalmuscle. The cDNA of the β-subunit is not described herein as it is wellknown in the art, Isom, et al., Neuron 12:1183-1194 (1994). However, itis to be understood that by combining the known sequence for theβ-subunit with the α-subunit sequence described herein, one may obtainthe complete rat peripheral nerve, voltage-gated, TTX-resistant sodiumchannel.

Functional expression in Xenopus oocytes shows that PN3 is avoltage-gated sodium channel with a depolarized activation potential,slow inactivation kinetics, and resistant to a high concentration ofTTX. PN3 may correspond to the sodium channel mediating TTX-resistantcurrents in small neurons of the DRG, that have been described in theliterature. See for example, Kostyuk, et al., Neurosci. 6:2423-2430(1981); McLean, et al., Molec. Cell. Biochem. 80:95-107 (1988); Roy, etal., supra; Caffrey, et al., Brain Res. 592:283-297 (1992); Elliott, etal., J. Physiol. 463:39-56 (1993); and Ogata, et al., J. Physiol.466:9-37 (1993).

Northern blot analysis indicates that PN3 is encoded by an ˜7.5 kbtranscript and nucleotide sequence analysis of the PN3 cDNA identifies a5868-base open reading frame, shown in FIG. 1. The deduced amino acidsequence of PN3, shown in FIG. 2 exhibits the primary structuralfeatures of an α-subunit of a voltage-gated sodium channel.

The present invention also includes the use of the voltage-gated,TTX-resistant sodium channel α-subunit as a therapeutic target forcompounds to treat disorders of the peripheral nervous system including,but not limited to, allodynia, hyperalgesia, diabetic neuropathy,traumatic injury and AIDS-associated neuropathy. The invention allowsfor the manipulation of genetic materials by recombinant technology toproduce polypeptides that possess the structural and functionalcharacteristics of the voltage-gated, TTX-resistant sodium channelα-subunit found in peripheral nerve tissue, particularly in sensorynerves. Site directed mutagenesis can be used to provide suchrecombinant polypeptides. For example, synthetic oligonucleotides can bespecifically inserted or substituted into the portion of the gene ofinterest to produce genes encoding for and expressing a specific mutant.Random degenerate oligonucleotides can also be inserted and phagedisplay techniques can be used to identify and isolate polypeptidespossessing a functional property of interest.

Sodium channels in peripheral nerve tissue play a large role in thetransmission of nerve impulses, and therefore are instrumental inunderstanding neuropathic pain transmission. Neuropathic pain falls intotwo categories: allodynia, where a normally non-painful stimulus becomespainful, and hyperalgesia, where a usually normal painful stimulusbecomes extremely painful. The ability to inhibit the activity of thesesodium channels, i.e., reduce the conduction of nerve impulses, willaffect the nerve's ability to transmit pain. Selective inhibition ofsodium channnels in sensory neurons such as dorsal root ganglia willallow the blockage of pain impulses without complicating side effectscaused by inhibition of sodium channels in other tissues such as brainand heart. In addition, certain diseases are caused by sodium channelsthat produce impulses at an extremely high frequency. The ability toreduce the activity of the channel can then eliminate or alleviate thedisease. Accordingly, potential therapeutic compounds can be screened bymethods well known in the art, to discover whether they can inhibit theactivity of the recombinant sodium channel of the invention. Barram, M.,et al., Naun-Schmiedeberg's archives of Pharmacology, 347: 125-132(1993) and McNeal, E. T. et al., J. Med. Chem., 28: 381-388 (1985). Forsimilar studies with the acetyl choline receptor, see, Claudio et al.,Science, 238: 1688-1694 (1987).

The sodium channel of the present invention has the most restrictivetissue distribution of the channels that have been studied. This is ofsignificant value to develop therapeutics that will have a specifictarget, i.e., that will not inhibit a particular channel in a wide rangeof tissues. Seven main tissue types were screened by RT-PCR forexpression of the unique 410 base amplicon corresponding to positions5893-6302 of SEQ ID NO:1. PN3 was present in three of the tissuesstudied: DRG, nodose ganglia and sciatic nerve tissue. PN3 was notpresent in the remaining tissues studied: brain, spinal cord, heart orskeletal muscle tissue. In view of the previous detection of a sodiumchannel PN1 mRNA in the peripheral nervous system, (D'Arcangelo et al)other tissues were screened by RT-PCR for the presence of PN1. PN1 wasdetected in brain, heart, spinal cord and superior cervical ganglia,under conditions in which PN3 was not detected. A tissue distributionprofile of human PN3 was determined by analysis of RNA from selectedhuman tissues and commerically available cDNA libraries by RT-PCR. hPN3was present in two of the tissues studied: DRG and sciatic nerve tissue.hPN3 was not present in the remaining tissues studied: brain, spinalcord, heart, or skeletal muscle tissue.

This invention is directed to inhibiting the activity of PN3 in DRG,nodose ganglia and sciatic nerve tissues. However, it is to beunderstood that further studies may reveal that PN3 is present in othertissues, and as such, those tissues can also be targeted areas. Forexample, the detection of PN3 mRNA in nodose ganglia suggests that PN3may conduct TTX-resistant sodium currents in this and other sensoryganglia of the peripheral nervous system. In addition, it has been foundthat proteins not normally expressed in certain tissues, are expressedin a disease state. Therefore, this invention is intended to encompassthe inhibition of PN3 in tissues and cell types where the protein isnormally expressed, and in those tissues and cell types where theprotein is only expressed during a disease state.

Another significant characteristic of PN3 is that it is TTX-resistant.It is believed that TTX-resistant sodium channels play a key role intransmitting nerve impulses relating to sensory inputs such as pain andpressure. This will also facilitate the design of therapeutics that canbe targeted to a specific area such as the peripheral nerve tissue.Studies of the TTX-resistant site on the protein will facilitate thedevelopment of a selective inhibitor. This site is shown in FIG. 2 (♦).It is believed that key amino acid residues in certain domains of thesodium channnel are critical for TTX resistance. Satin, Kyle et al.Science, 256:1202-1205(1992). In the cardiac sodium channel, mutation ofCys³⁷⁴→Phe or Tyr rendered the channel TTX sensitive. This positioncorresponds to Ser³⁵⁶ in PN3 (SEQ ID NO: 2), and Ser³⁵⁷ in hPN3 (SEQ IDNO:10) It is believed that non-aromatic residues at this site confer TTXresistance to the sodium channel. Peripheral nerve sodium channelsmutated at positions analogous to amino acid residue 356 and DNAsequences encoding therefor are also contemplated by this invention.Specific embodiments include the amino acid sequence of SEQ ID NO:2 inwhich Ser³⁵⁶ is replaced by a non aromatic residue, and DNA sequencesencoding therefor. Typical aromatic residues are phenylalanine, tyrosineand tryptophan. Typical non-aromatic residues are threonine, valine,cysteine, aspartate and arginine. Site directed mutagenesis can identifyadditional residues critical for TTX resistance and provide targets fornew therapeutic compounds.

The invention also pertains to an assay for inhibitors of peripheralnerve TTX-resistant sodium channel protein comprising contacting acompound suspected of being an inhibitor with expressed sodium channeland measuring the activity of the sodium channel. The compound can be asubstantially pure compound of synthetic origin combined in an aqueousmedium, or the compound can be a naturally occurring material such thatthe assay medium is an extract of biological origin, such as, forexample, a plant, animal, or microbial cell extract. PN3 activity can bemeasured by methods such as electrophysiology (two electrode voltageclamp or single electrode whole cell patch clamp), guanidinium ion fluxassays and toxin-binding assays. An “inhibitor” is defined as generallythat amount that results in greater than 50% decrease in PN3 activity,preferably greater than 70% decrease in PN3 activity, more preferably,greater than 90% decrease in PN3 activity.

In addition, the present invention encompasses a method of alleviatingpain by inhibiting the activity of the peripheral nerve TTX-resistantsodium channel comprising administering a therapeutically effectiveamount of a compound having an IC₅₀ of 10 μM or less, preferably ≦1 μM.Potential therapeutic compounds are identified based on their ability toinhibit the activity of PN3. Therefore, the aforementioned assay can beused to identify compounds having a therapeutically effective IC₅₀.

The term “IC₅₀” refers to the concentration of a compound that isrequired to inhibit by 50% the activity of expressed PN3 when activityis measured by electrophysiology, flux assays and toxin-binding, assays,as mentioned above.

The basic molecular biology techniques employed in accomplishingfeatures of this invention, such as RNA and DNA and plasmid isolation,restriction enzyme digestion, preparation and probing of a cDNA library,sequencing clones, constructing expression vectors, transforming cells,maintaining and growing cell cultures and other general techniques arewell known in the art, and descriptions of such techniques can be foundin general laboratory manuals such as Molecular Cloning: A LaboratoryManual by Sambrook, et al. (Cold Spring Harbor Laboratory Press, 2ndedition, 1989). Accordingly, the following examples are merelyillustrative of the techniques by which the invention can be practiced.Abbreviations BSA bovine serum albumin Denhardt's 0.02% BSA, 0.02%polyvinyl-pyrrolidone, 0.02% Ficoll solution (0.1 g BSA, 0.1 g Ficolland 0.1 g poly-vinylpyrrolidone per 500 ml) DRG dorsal root ganglia EDTAEthylenediaminetetraacetic acid, tetrasodium salt MEN  20 mM MOPS, 1 mMEDTA, 5 mM sodium acetate, pH 7.0 MOPS 3-(N-morpholino)propanesulfonicacid (Sigma Chemical Company) PN3 peripheral nerve sodium channel type 3PNS peripheral nervous system SDS sodium dodecyl sulfate SSC 150 mMNaCl, 15 mM sodium citrate, pH 7.0 SSPE  80 mM NaCl, 10 mM sodiumphosphate, 1 mM ethylenediaminetetraacetate, pH 8.0 TEV two electrodevoltage clamp TTX tetrodotoxin Sigma Chemical Company

EXAMPLES

Materials

The plasmid, pBK-CMV, was obtained from Stratagene (La Jolla, Calif.);plasmid, pBSTA, was obtained from A. Goldin at the University ofCalifornia, Irvine and is described by Goldin, et al., in Methods inEnzymology (Rudy & Iverson, eds) 207:279-297.

Example 1 Hybridization of mRNA from Rat DRG

Lumbar DRG #4 and #5 (L4 and L5), brain and spinal cord were removedfrom anesthetized adult male Sprague-Dawley rats under a dissectingmicroscope. The tissues were frozen in dry ice and homogenized with aPolytron homogenizer; the RNA was extracted by the guanidineisothiocyanate procedure (Chomczynksi, et al., Anal. Biochemistry162:156-159, 1987). Total RNA (5 μg of each sample) was dissolved in MENbuffer containing 50% formamide, 6.6% formaldehyde and denatured at 65°C. for 5-10 min. The RNA was electrophoresed through a 0.8% agarose gelcontaining 8.3% formaldehyde in MEN buffer. The electrode buffer was MENbuffer containing 3.7% formaldehyde; the gel was run at 50 V for 12-18hr.

After electrophoresis, the gel was rinsed in 2×SSC and the RNA wastransferred to a Duralose membrane (Stratagene) with 20×SSC by capillaryaction; the membrane was baked under vacuum at 80° C. for 1 hr. Themembrane was prehybridized in 50% formamide, 5×SSC, 50 mM sodiumphosphate, pH 7.1, 1× Denhardt's solution, 0.5% SDS, and sheared,heat-denatured salmon sperm DNA (1 mg/ml) for 16 hr at 42° C. Themembrane was hybridized in 50% formamide, 5×SSC, 50 mM sodium phosphate,pH 7.1, 1× Denhardt's solution, 0.5% SDS, and sheared, heat-denaturedsalmon sperm DNA (200 μg/ml) with a ³²P-labeled cRNA probe (ca. 1-3×10⁶cpm/ml) that was complementary to nucleotides 4637-5868 of the rat brainIIA sodium channel μ-subunit sequence for 18 hr at 42° C.; the cRNAprobe was synthesized in vitro with T7 RNA polymerase (Pharmacia) usingpEAF8 template DNA, Noda et al., Nature, 320:188-192 (1986), (obtainedfrom W. A. Catterall, University of Washington) that had been linearizedwith BstEII.

The membrane was rinsed with 2×SSC, 0.1% SDS at room temperature for 20min and then washed sequentially with: 2×SSC, 0.1% SDS at 55° C. for 30min, 0.2×SSC, 0.1% SDS at 65° C. for 30 min, 0.2×SSC, 0.1% SDS at 70° C.for 30 min, and 0.2×SSC, 0.1% SDS, 0.1% sodium pyrophosphate at 70° C.for 20 min. The filter was exposed against Kodak X-omat AR film at −80°C. with intensifying screens for up to 2 weeks.

Size markers, including ribosomal 18S and 28S RNAs and RNA markers(GIBCO BRL), were run in parallel lanes of the gel. Their positions weredetermined by staining the excised lane with ethidium bromide (0.5μg/ml) followed by photography under UV light. The pEAF8 probehybridized to mRNAs in the DRG sample with sizes of 11 kb, 9.5 kb, 7.3kb, and 6.5 kb, estimated on the basis of their positions relative tothe standards. When the membrane was reprobed with a cloned fragmentcorresponding to the novel sodium channel domain IV (SEQ ID NO:3), the7.3 kb transcript is detected in the DRG mRNA, but this size mRNA is notdetected in brain or spinal cord. The probe's sequence (SEQ ID NO:3) wasas follows: 1 CTCAACATGG TTACGATGAT GGTGGAGACC GACGAGCAGG GCGAGGAGAA 51GACGAAGGTT CTGGGCAGAA TCAACCAGTT CTTTGTGGCC GTCTTGACGG 101 GCGAGTGTGTGATGAAGATG TTCGCCCTGC GACAGTACTA TTTCACCAAC 151 GGCTGGAACG TGTTCGACTTCATAGTGGTG ATCCTGTCCA TTGGGAGTCT 201 GCTGTTTTCT GCAATCCTTA AGTCACTGGAAAACTACTTC TCCCCGACGC 251 TCTTCCGGGT CATCCGTCTG GCCAGGATCG GCCGCATCCTCAGGCTGATC 301 CGAGCAGCCA AGGGGATTCG CACGCTGCTC TTCGCCCTCA TGATGTCCCT351 GCCCGCCCTC TTCAACATCG GCCTCCTCCT CTTCCTCGTC ATGTTCATCT 401ACTCCATCTT CGGCATGGCC AGCTTGGCTA ACGTCGTGGA CGAGGCCGGC 451 ATCGACGACATGTTGAACTT CAAGACCTTT GGCAAGAGCA TGCTGTGCCT 501 GTTCCAGATC ACCACCTCGGCCGGCTGGGA CGGCCTCCTC AGCCCCATCC 551 TCAACACGGG GCCTCCCTAC TGCGACCCCAACCTGCCCAA CAGCAACGGC 601 TCCCGGGGGA ACTGCGGGAG CCCGGCGGTG GGCATCATCTTCTTCACCAC 651 CTACATCATC ATCTCCTTCC TRATCGTGGT CAACATGTAT ATCGCAGTCA701 TCThe probe was obtained as follows: RT-PCR was performed on RNA isolatedfrom rat DRG using degenerate ologonucleotide primers that were designedbased on the homologies between known sodium channels in domain IV. Thedomain IV products were cloned in to a plasmid vector, transformed intoE. coli and single colonies isolated. The domain IV specific PCRproducts obtained from several of these colonies were individuallysequenced. Cloned novel domain IV sequence (SEQ ID NO:3) was labelledwith ³²P by random priming and used to probe a Northern blot of ratbrain, spinal cord and DRG RNA.

Nucleotides 16-689 of the probe's sequence corresponds to nucleotides4502-5175 of FIG. 1 (excludes the degenerate primer sequence). The endsof the probe are not identical to the sequence in FIG. 1 because of thenature of the primers used for PCR. In addition, the probe has onecentral base that is different from that of the corresponding domain IVregion in FIG. 1; the base at position 141 in the probe is a thymineresidue while the corresponding base (position 4627) in FIG. 1 is acytosine residue. This is likely due to an error made by the enzymeduring PCR amplification; it is not a simple sequencing error.

This result suggests that the 7.3 kb mRNA encoding PN3 is uniquelyexpressed in peripheral neurons and that SEQ ID NO:3 can be used todetect/isolate/differentiate peripheral nervous system sodium channelsfrom others.

Example 2 Construction & Screening of cDNA Library from Rat DRG

EcoRI-adapted cDNA was prepared from normal adult male Sprague-Dawleyrat DRG poly(A)⁺ RNA using the SuperScript Choice System (GIBCO BRL).cDNA (>4 kb) was selected by sucrose gradient fractionation as describedby Kieffer, Gene 109:115-119 (1991). The cDNA was then ligated into theZap Express vector (Stratagene), and packaged with the Gigapack II XLlambda packaging extract (Stratagene). Phage (3.5×10⁵) were screened byfilter hybridization with a ³²P-labelled probe (rBIIa, bases 4637-5868of Auld, et al., Neuron 1:449-461 (1988)). Filters were hybridized in50% formamide, 5×SSPE, 5× Denhardt's solution, 0.5% SDS, 250 μg/mlsheared, denatured salmon sperm DNA, and 50 mM sodium phosphate at 42°C. and washed in 0.5×SSC/0.1%. SDS at 50° C. Positive clones wereexcised in vivo into pBK-CMV using the ExAssist/XLOLR system(Stratagene). Southern blots of EcoRI-digested plasmids were hybridizedwith the ³²P-labelled DNA probe, (SEQ ID NO: 3), representing a noveldomain IV segment amplified from DRG RNA with degenerate oligonucleotideprimers.

Southern filters were hybridized in 50% formamide, 6×SSC, 5× Denhardt'ssolution, 0.5% SDS, and 100 μg/ml sheared, denatured salmon sperm DNA at42° C. and were washed in 0.1×SSC/0.1% SDS at 65° C.

A plasmid containing a full-length cDNA was identified, designatedperipheral nerve sodium channel type 3 (“PN3”), and sequenced on bothstrands. For oocyte expression analysis, the PN3 cDNA was excised fromthe vector and, after blunting the ends subcloned into pBSTA.

The deduced amino acid sequence (SEQ ID NO:2) of PN3 is shown in FIG. 2.PN3 contains four homologous domains, represented as the regions markedI-IV. Each domain consists of six putative α-helical transmembranesegments, represented as S1-S6. The positively charged residues in thevoltage sensor (S4 segments) and the inactivation gate between IIIS6 andIVS1 are highly conserved in PN3. Sites for cAMP-dependentphosphorylation and N-linked glycosylation shown experimentally to existin other sodium channels (See Catterall, Physiol. Rev. 72:S15-S48(1992)) are also present in PN3. This is shown in FIG. 2 by the symbols“°” and “●”, representing the potential cAMP-dependent phosphorylationsites and potential N-linked glycosylation sites, respectively. Symbolsalso indicate the TTX resistance site (♦) and the termination codon (*).

Also identified were several PN3 partial clones which contained a singleadditional Gln between Pro⁵⁸⁴ and Ala⁵⁸⁵ (

) of the full-length PN3 sequence. The corresponding RNA had threeadditional nucleotides, thus establishing that the extra amino acid wasnot a cloning artifact.

Similar procedures have furnished partial clones coding for additionalsodium channnel proteins in dorsal root ganglia. Sequencing data ofthese clones revealed that one of these other clones had a sequencewhich encoded the disclosed partial amino acid sequence of the sodiumchannel protein, PN1.

Example 3 Comparison with Amino Acid Seouences

Sequence analyses were done to compare the amino acid sequence of PN3and selected cloned rat sodium channels, using the Gap, PileUp, andDistances programs of the Wisconsin Sequence Analysis Package (GeneticsComputer Group, Inc.). The sodium channels evaluated were as follows:TABLE 1 cloned rat percent amino acid sodium channel similarity with PN3rBI 75.4 rBII 75.5 rBIII 75.5 rSkM1 76.0 rH1 77.6where rBI and rBlI are rat brain sodium channels I and II, respectively,described in Noda, et al., Nature 320:188-192 (1986); rBIII is rat brainsodium channel III, described in Joho, et al., Molec. Brain Res.7:105-113 (1990); rSkMl is rat skeletal muscle, described in Trirmer, etal., Neuron 3:33-49 (1989); and rHl is rat heart sodium channel,described in Rogart, et al., PNAS 86:8170-8174 (1989). The sequencehomology between PN3 and the TTX-insensitive cardiac channel and theirslow kinetics suggest that they belong to a unique subfamily of sodiumchannels.

Brain, spinal cord, DRG, nodose ganglia, superior cervical ganglia,sciatic nerve, heart and skeletal muscle tissues were isolated fromanesthetized, normal adult male Sprague-Dawley rats and were stored at−80° C. RNA was isolated from each tissue using RNAzol (Tel-Test, Inc.).Random-primed cDNA was reverse transcribed from 500 ng of RNA from eachtissue. PCR primers corresponding to positions 5893-5912 of FIG. 1(forward primer): 5′ AAG GCA CTC AGG CAT GCA CA 3′ (SEQ ID NO: 4)

and antisense corresponding to positions 6282-6302 of FIG. 1 (reverseprimer): 5′ TGG CCG ACT CAC AGG TAT TG 3′ (SEQ ID NO: 5)

targeted the 3′-untranslated region of PN3 and defined a 410 bp amplicon(SEQ ID NO:6) corresponding to positions 5893-6302 of FIG. 1: 1AAGGCACTCA GGCATGCACA GGGCAGGTTC CAATGTCTTT CTCTGCTGTG 51 CTAACTCCTTCCCTCTGGAG GTGGCACCAA CCTCCAGCCT CCACCAATGC 101 ATGTCACTGG TCATGGTGTCAGAACTGAAT GGGGACATCC TTGAGAAAGC 151 CCCCACCCCA ATAGGAATCA AAA-GCCAAGGATACTCCTCC ATTCTGACGT 201 CCCTTCCGAG TTCCCAGAAG ATGTCATTGC TCCCTTCTGTTTGTGACCAG 251 AGACGTGATT CACCAACTTC TCGGAGCCAG AGACACATAC CAAAGACTTT301 TCTGCTGGTG TCGGGCAGTC TTAGAGAAGT CACGTAGGGG TTGGCACTGA 351GAATTAGGGT TTGCATGCCT GCATGCTCAC AGCTGCCGGA CAATACCTGT 401 GAGTCGGCCAThermal cyclek parameters: 30 s/94° C., 30 s/57° C., 1 min/72° C. (24cycles); 30 s/94° C., 30 s/57° C., 5 min/72° C. (1 cycle). A positivecontrol (1 ng pBK-CMV/PN3) and a no-template control were also included.cDNA from each tissue was also PCR amplified using primers specific forglyceraldehyde-3-phosphate dehydrogenase to demonstrate templateviability, as described by Tso, et al., Nucleic Acid Res. 13:2485-2502(1985). PN3 PCR amplicons from nodose ganglia and sciatic nerve wereconfirmed by nucleotide sequence analysis.

Tissue distribution profile of PN3 by analysis of RNA from selected rattissues by RT-PCR was as follows: TABLE 2 Tissue RT-PCR Brain − Spinalcord − DRG + Nodose ganglia + Sciatic nerve + Heart − Skeletal muscle −Superior cervical ganglia −As can be seen from Table 2, RNA analysis suggests that PN3 mRNAexpression is limited to DRG and nodose ganglia of the PNS. PN3 mRNA wasreadily detected in DRG and nodose ganglia by amplification for only 25cycles; a small amount of PN3 mRNA was also detected in sciatic nerveafter 25 cycles. PN3 mRNA was not detected in brain, spinal cord, heart,skeletal muscle, or superior cervical ganglia after 35 cycles ofamplification.

Additional RT-PCR analyses of DRG mRNA detected rBI, RBII, RBIII, andrHl, along with peripheral nerve sodium channel type 1 (PN1), describedin D'Arcangelo, et al., supra. PN1 was also detected in brain, heart,spinal cord and superior cervical ganglia under conditions in which PN3was not detected.

Example 4 In Situ Hybridization

Oligonucleotide probe sequences were identified from the unique3′-untranslated region of PN3 (sense and antisense probes werecomplementary to each other). The sense probe had the followingsequence: (SEQ ID NO: 7) 5′ AGG CAC TCA GGC ATG CAC AGG GCA GGT TCC AATGTC TTT CTC TGCT 3′

and the antisense had the following sequence: (SEQ ID NO: 8) 3′ TCC GTGAGT CCG TAC GTG TCC CGT CCA AGG TTA CAG AAA GAG ACG A 5′

both corresponding to positions 5894-5939.

Normal rats were perfused with 4% paraformaldehyde; lumbar DRG #4-#6(L4-L6) were removed, postfixed in the same solution, and cryoprotectedin 20% sucrose. Frozen sections (10 μm) were cut and hybridizedovernight at 39° C. in a solution containing ³⁵S-ATP labelledoligonucleotides (specific activity=5×10⁷-1×10⁸ cpm/μg), 50% formamide,4×SSC, 0.5 mg/ml salmon sperm DNA, and 1× Denhardt's solution. Sectionswere washed over a period of 6 hours in 2×-0.2×SSC containing0.1%-β-mercaptoethanol, dehydrated in a series of ethanols (50%-100%)containing 0.3 M ammonium acetate, and apposed to sheet film (AmershamBmax) or emulsion (Amersham LM-1) for 2 and 5 weeks, respectively. Thecell surface area of all neurons with a distinct nucleus was measuredfrom stained sections obtained from 3 ganglia using a computerized imageanalysis system (Imaging Research, Inc.).

In situ hybridization of these PN3-specific oligonucleotide probes torat DRG showed that PN3 mRNA is specifically expressed in neuronalcells. The labelled cells were distributed throughout the ganglia, butmost labelled neurons were small in somal area (<1500 μm²). PN3 mRNA wasnot detected in the axons of L4 and L5 DRG neurons by in situ analysis;however, RT-PCR analysis detected PN3 mRNA in the sciatic nerve. Thisdifference is attributed to the greater sensitivity of RT-PCRamplification versus in situ hybridization.

FIG. 3 depicts a frequency histogram of somal area summed from 10 μmsections through three ganglia. The area of labelled neurons isrepresented by filled bars (mean±standard deviation: 725±265 μm²; n=44),the area of all neurons is represented by open bars (1041±511 μm²;n=130).

Example 5 Expression of Full Length Clone

cRNA was prepared from PN3 subcloned into pBSTA using a T7 in vitrotranscription kit (Ambion, mMessage mMachine) and was injected intostage V and VI Xenopus oocytes using a Nanojector (Drummond), asdescribed in Goldin, supra. After 2.5 days at 20° C., the oocytes wereimpaled with agarose-cushion electrodes (0.3-0.8 MOhm) andvoltage-clamped with a Geneclamp 500 amplifier (Axon Instruments) in TEVmode. See Schreibmayer, et al., Pflugers Arch. 426:453-458 (1994).

Stimulation and recording were controlled by a computer running pClamp(Axon Instruments), Kegel, et al. J. Neurosci. Meth. 12:317-330 (1982).Oocytes were perfused with a solution containing: 81 mM NaCl, 2 mM KC 1,1 mM MgCl₂, 0.3 mM CaCl₂, 20 mM Hepes-NaOH, pH 7.5.

FIG. 4(a) shows the currents produced by step depolarizations of anoocyte injected with 18 ng of PN3 cRNA from a holding potential of −100mV to −30 mV through +50 mV. No inward current was observed in oocytesinjected with water. Data were collected using the Geneclamp hardwareleak subtraction, filtered at 5 kHz with a 4-pole Bessel filter, andsampled at 50 kHz. Expression of PN3 produced an inward current withslow inactivation kinetics, similar to that of the rBIIa (Patton, etal., Neuron 7:637-647 (1991)) and rSkMI α-subunits expressed in theabsence of the β1-subunit. However, coinjection of 1.3 ng of humansodium channel β1-subunit (hSCNβ1, as described by McClatchey, et al.,Hum. Molec. Gen. 2:745-749 (1993)) cRNA with PN3 cRNA did not acceleratethe inactivation kinetics; coexpression of this quantity of hSCNβ1 cRNAwith rBIIa cRNA was sufficient to accelerate maximally the inactivationkinetics of rBIIa. Therefore, PN3 may possess inherently slow kinetics.The amino acid sequence of hSCNβ1 and rat brain sodium channelβ1-subunit (rSCNβ1, as described by Isom, Science 256:839-842 (1992))are 96% identical; rSCNβ1 and a cloned rat DRG β1-subunit have identicalamino acid sequences.

Examination of the current/voltage relationship reveals a strikinglydepolarized channel activation potential, as can be seen in FIG. 4(b).In this expression system, PN3 exhibits little or no activation at 0 mV,whereas most cloned sodium channels generally begin to activate between−60 and −30 mV. See for example, Joho, et al., supra; Patton, et al.,supra; Trimmer, et al., supra; and Cribbs, et al., FEBS Lett. 275:195200(1990). To demonstrate the sodium dependence of these induced currents,the extracellular sodium concentration was reduced from ˜91 mM to ˜50 mMby substituting N-methyl-D-glucamine. The resulting inward current wasreduced and the reversal potential was shifted from ⁺43 mV to ⁺12 mV.Further reduction of the extracellular sodium concentration to −21 mMshifted the reversal potential to −22 mV.

Sodium channels are distinctively sensitive or insensitive toneurotoxins such as TTX. The TTX-sensitive brain and skeletal musclesodium channels are blocked by nanomolar TTX concentrations, whereas theTTX-insensitive cardiac sodium channels are blocked by micromolar TTXconcentrations. In rat heart sodium channel 1 (RH1), Cys³⁷⁴ is acritical determinant of TTX-insensitivity, as shown in Satin, et al.,Science 256:1202-1205(1992); in the TTX-sensitive rBI, RBII, RBIII, andrSkMl, the corresponding residue is either Phe or Tyr. In PN3, thisposition is occupied by a Ser residue (Ser³⁵⁶). When expressed inXenopus oocytes, the PN3 sodium current is highly resistant to TTX(IC₅₀≧100 μM). FIG. 4(c) shows the concentration dependence for TTXblockage of PN3 sodium current (mean and range; n=2). For thisexperiment, the oocytes were depolarized from −100 mV to +20 mV forapproximately 10 ms at 0.1 Hz; P/−4 leak subtraction was used(Bezanilla, et al., J. Gen. Physiol. 70:549-566 (1977)). There was aslow “rundown” of the current with time, and a correction was made forthe resulting sloping baseline. Varying concentrations of TTX in bathsolution were perfused over the oocyte and the current amplitude wasallowed to attain steady-state before the effect was recorded.

Example 6 Specific Antibody for PN3

A 15-mer peptide(CDPNLPNSNGSRGNC) was synthesized and and coupled tokeyhole limpet hemocyanin prior to injection into rabbit. The sequenceof the peptide corresponded to residues 1679-1693 of FIG. 2. Out of thetwo rabbits injected with the antigen only one yielded antiserum that isuseful in characterizing the PN3 ion channel protein. The antiserum wasthen affinity purified by passage through a peptide affinity column.Immunohistochemical experiments substantiated earlier observations usingPN3 antisense oligonucleotide probe (in situ hybridization) that PN3 waslargely localized in the small sensory neurons of the dorsal rootganglia (DRG). In addition to the sensory neurons of DRG, a small numberof transmission neurons in lamina 10 of the spinal cord showedimmunoreactivity with the PN3 antibody. Because only a subset of neuronswere positive for PN3 expression, PN3 mRNA could have been undetectableby RT-PCR assays using the entire spinal cord (dilution effect).

Immunoprecipitation experiments indicated that PN3 expressing Chinesehamster lung (CHL) cells had a ˜250 kD protein which corresponds to theα-subunit. Since the peptide sequence does not match with any otherprotein, particularly other sodium channels, the antibody could be veryspecific reagent to characterize the PN3 protein. In addition, theantibody could be used as a tool to understand the role of PN3 innociceptive pathways. By infusing the antibody in rats so that it‘soaks-up’ all available PN3 protein and testing the rats in pain modelsone could begin to investigate the role of PN3 function in painpathways.

Example 7 Variants of PN3

A variant of PN3, PN3a has been identified by sequencing a full-lengthcDNA clone. The sequence of PN3a is identical to that of PN3, includingthe 5′- and 3′-UTR, except for an additional amino acid, Gln, at Pro⁵⁸⁴of PN3 set forth in SEQ ID NO: 2. The insertion of Gln in this regionwas previously reported from RT-PCR experiments. PN3a expressed at ahigher level than PN3 in Xenopus oocytes and exhibited otherwise thesame characteristics as PN3, such as resistance to high concentrationsof TTX and depolarized activation potential.

Another cDNA clone had the same sequence as PN3 in the coding region,but the 5′-UTR sequence diverged 33 bp upstream of the start codon, ATG.Another cDNA clone had a longer 3′-UTR with an additional ˜1 KB and asecond polyadenylation signal. These sequence differences in thenoncoding region indicate that regulation of the use of differentpolyadenylation signal and/or interaction with different transcriptionelements of the 5′-UTR could play a role in expression of PN3 indistinct subsets of sensory neurons.

Although the foregoing invention has been described in some detail byway of illustration and example for purposes of clarity andunderstanding, it will be obvious that certain changes and modificationsmay be practiced within the scope of the appended claims.

1-20. (canceled)
 21. An antibody which specifically binds to apolypeptide comprising the amino acid sequence of SEQ ID NO:10.
 22. Theantibody of claim 21, wherein said antibody is: a) a monoclonalantibody; or b) a polyclonal antibody.
 23. A method of producing theantibody of claim 21, comprising: a) immunizing an animal with apolypeptide comprising the amino acid sequence of SEQ ID NO:10 or afragment thereof, and b) producing an antibody which specifically bindsto said polypeptide.
 24. An antibody fragment which specifically bindsto a polypeptide comprising the amino acid sequence of SEQ ID NO:10.